Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

Evan Scott Glazer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5796-0542; OpenAlex author ID A5088291412. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
30
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 3 papers · 2020: 1 paper · 2021: 2 papers · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 3 papers

Papers 17

  1. Anti-mitotic agent SB-216 overcomes taxane resistance in castration-resistant prostate cancer and exhibits anti-tumour efficacy in pancreatic cancer. Co-author DOI 10.1111/bph.70294↗
  2. The Impact of Race and Socioeconomic Status on Management of Potentially Resectable Pancreatic Cancer: Analysis From a Metropolitan Area in the Southeast Unite… Co-author DOI 10.1177/00031348251399190↗
  3. Dual targeting of oncogenic microtubules and mitochondria in PDAC. Last author DOI 10.18632/oncoscience.641↗
  4. Reprogramming oncogenic mitochondria in pancreatic adenocarcinoma through BRD4 inhibition leads to programmed cell death. Last author DOI 10.1016/j.jpet.2025.103751↗
  5. Confirmatory Clinical Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/curroncol32110638↗
  6. Bromo- and Extra-Terminal Domain Inhibitors Induce Mitochondrial Stress in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1535-7163.mct-23-0149↗
  7. The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF-β receptor plus dual checkpoint inhibition maintains antit… Last author DOI 10.1002/mc.23401↗
  8. TGF-β Alters the Proportion of Infiltrating Immune Cells in a Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1007/s11605-021-05087-x↗
  9. Tumor Location in the Pancreatic Tail Is Associated with Decreased Likelihood of Receiving Chemotherapy for Pancreatic Adenocarcinoma. Co-author DOI 10.1007/s11605-022-05381-2↗
  10. Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression. Last author DOI 10.1007/s13402-021-00594-0↗
  11. Traveling for Pancreatic Cancer Care Is Worth the Trip. Last author DOI 10.1177/0003134820951484↗
  12. The utilization and impact of adjuvant therapy following neoadjuvant therapy and resection of pancreatic adenocarcinoma: does more really matter? Co-author DOI 10.1016/j.hpb.2020.02.011↗
  13. TGF-β Inhibitors in Metastatic Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1007/s12029-018-00195-5↗
  14. Molecular Alterations Associated with DNA Repair in Pancreatic Adenocarcinoma Are Associated with Sites of Recurrence. Last author DOI 10.1007/s12029-018-0073-8↗
  15. Rising BMI Is Associated with Increased Rate of Clinically Relevant Pancreatic Fistula after Distal Pancreatectomy for Pancreatic Adenocarcinoma. Last author DOI 10.1177/000313481908501232↗
  16. TGFβ1 overexpression is associated with improved survival and low tumor cell proliferation in patients with early-stage pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.13533↗
  17. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal… Co-author DOI 10.1016/j.surg.2016.04.039↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Paxton Vandiver Dickson · 7 shared papers, 2019–2026 · strength 1.07
  2. Chun Cai · 3 shared papers, 2025–2026 · strength 0.86
  3. Michael W. Spinrad · 2 shared papers, 2025–2026 · strength 0.57
  4. Marcus A. Alvarez · 4 shared papers, 2019–2022 · strength 0.53
  5. Wěi Li · 2 shared papers, 2025–2026 · strength 0.53
  6. Stephen W. Behrman · 4 shared papers, 2019–2022 · strength 0.49
  7. Danny Yakoub · 3 shared papers, 2021–2022 · strength 0.39
  8. Justin A. Drake · 3 shared papers, 2019–2022 · strength 0.39
  9. Gabriela L. Aitken · 1 shared paper, 2026 · strength 0.36
  10. Devanshi D. Patel · 1 shared paper, 2026 · strength 0.36
  11. Manjul Rana · 2 shared papers, 2022–2023 · strength 0.34
  12. Mehdi Chaib · 2 shared papers, 2022 · strength 0.31
  13. Rui Wang · 1 shared paper, 2026 · strength 0.29
  14. Norma Alonzo Palma · 1 shared paper, 2025 · strength 0.25
  15. Patricio Marcelo Polanco · 1 shared paper, 2025 · strength 0.25
  16. Lisa A. Ford · 1 shared paper, 2025 · strength 0.25
  17. Thomas Charles King · 1 shared paper, 2025 · strength 0.25
  18. Randall E. Brand · 1 shared paper, 2025 · strength 0.25
  19. Tamas A. Gonda · 1 shared paper, 2025 · strength 0.25
  20. Jose Gilberto Trevino · 1 shared paper, 2025 · strength 0.25
  21. Erkut Hasan Borazanci · 1 shared paper, 2025 · strength 0.25
  22. Syed M. Hussain · 2 shared papers, 2019–2021 · strength 0.24
  23. José M. Pimiento · 2 shared papers, 2016–2017 · strength 0.17
  24. Mokenge Peter Malafa · 2 shared papers, 2016–2017 · strength 0.17
  25. Kasia Trebska-McGowan · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.